Regeneron Pharmaceuticals Company Profile (NASDAQ:REGN)

About Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals logoRegeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:REGN
  • CUSIP: 75886F10
  • Web: www.regeneron.com
Capitalization:
  • Market Cap: $55.40047 billion
  • Outstanding Shares: 105,571,000
Average Prices:
  • 50 Day Moving Avg: $495.83
  • 200 Day Moving Avg: $415.60
  • 52 Week Range: $325.35 - $543.55
P/E:
  • Trailing P/E Ratio: 62.15
  • Foreward P/E Ratio: 42.43
  • P/E Growth: 2.17
Sales & Book Value:
  • Annual Revenue: $4.98 billion
  • Price / Sales: 10.88
  • Book Value: $46.09 per share
  • Price / Book: 11.14
Profitability:
  • EBIDTA: $1.55 billion
  • Net Margins: 19.34%
  • Return on Equity: 22.99%
  • Return on Assets: 14.77%
Debt:
  • Debt-to-Equity Ratio: 0.14%
  • Current Ratio: 2.80%
  • Quick Ratio: 2.45%
Misc:
  • Average Volume: 986,184 shs.
  • Beta: 1.67
  • Short Ratio: 2.46
 
Frequently Asked Questions for Regeneron Pharmaceuticals (NASDAQ:REGN)

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) issued its earnings results on Thursday, May, 4th. The company reported $2.92 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $2.50 by $0.42. The company had revenue of $1.32 billion for the quarter, compared to analysts' expectations of $1.30 billion. Regeneron Pharmaceuticals had a net margin of 19.34% and a return on equity of 22.99%. Regeneron Pharmaceuticals's quarterly revenue was up 9.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.57 EPS. View Regeneron Pharmaceuticals' Earnings History.

When will Regeneron Pharmaceuticals make its next earnings announcement?

Regeneron Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Regeneron Pharmaceuticals.

Where is Regeneron Pharmaceuticals' stock going? Where will Regeneron Pharmaceuticals' stock price be in 2017?

26 analysts have issued 12 month target prices for Regeneron Pharmaceuticals' stock. Their predictions range from $345.00 to $598.00. On average, they anticipate Regeneron Pharmaceuticals' share price to reach $472.96 in the next year. View Analyst Ratings for Regeneron Pharmaceuticals.

What are analysts saying about Regeneron Pharmaceuticals stock?

Here are some recent quotes from research analysts about Regeneron Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Regeneron’s key growth driver, Eylea, continues to drive revenues and the company is expanding the drug's label for additional indications. The FDA’s approval of Dupixent was a major boost to the company’s portfolio and Regeneron is evaluating the drug for additional indications like asthma. The approval of Kevzara (sarilumab) for the treatment of moderately-to-severely active rheumatoid arthritis both in the U.S.and EU will further diversify the company’s portfolio. On the other hand, although sales of Praluent have failed to impress due to the present payer utilization management restrictions in the U.S. and limited market access in Europe, the drug is expected to have blockbuster potential. Shares of the company have also outperformed the industry in the year so far." (7/4/2017)
  • 2. Cowen and Company analysts commented, "REGN reported Q1:17 U.S." (5/5/2017)
  • 3. BMO Capital Markets analysts commented, "We raise our price target to $412 but maintain our Market Perform rating on REGN following Dupixent approval in adult atopic dermatitis. While the approval was widely expected and reflects the strength of Dupixent's clinical profile, we believe the $37k gross price (~$30k net) is higher than expected (BMO: ~$25k prior) and could lead to even more aggressive management by payors. Thus, while we have updated our model to reflect Dupixent's actual price, we have slowed our ramp on our expectation for increased access restrictions given the therapy's high price." (3/28/2017)
  • 4. Robert W. Baird analysts commented, "We surveyed 30 dermatologists treating ~134 moderate-to-severe AD patients each on their expectations around the launches for Pfizer's Eucrisa and Regeneron/Sanofi's Dupixent, set for approval tomorrow. Docs highlighted the significant need for new mechanisms and therapeutic alternatives. Importantly, physician sentiment points to a market for Dupixent of about 300,000-350,000 patients, in line with management's expectations. We wouldn't be surprised to see an exceptionally strong launch here, but we continue to point out that consensus expectations are already building that in." (3/28/2017)

Who are some of Regeneron Pharmaceuticals' key competitors?

Who are Regeneron Pharmaceuticals' key executives?

Regeneron Pharmaceuticals' management team includes the folowing people:

  • P. Roy Vagelos M.D., Chairman of the Board
  • Leonard S. Schleifer M.D., Ph.D., President, Chief Executive Officer, Director
  • Robert E. Landry, Chief Financial Officer, Senior Vice President - Finance
  • Daniel P. Van Plew, Executive Vice President, General Manager - Industrial Operations and Product Supply
  • Neil Stahl Ph.D., Executive Vice President - Research and Development
  • Robert J. Terifay, Executive Vice President - Commercial
  • Joseph J. LaRosa, Senior Vice President, General Counsel, Secretary
  • Michael Aberman M.D., Senior Vice President - Strategy and Investor Relation
  • Peter Powchik M.D., Senior Vice President - Clinical Development
  • George D. Yancopoulos M.D., Ph.D., President and Chief Scientific Officer - Regeneron, Director

Who owns Regeneron Pharmaceuticals stock?

Regeneron Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Manning & Napier Advisors LLC (0.28%), Russell Investments Group Ltd. (0.14%), Rockefeller Financial Services Inc. (0.12%), Chevy Chase Trust Holdings Inc. (0.09%), National Pension Service (0.06%) and Bank of Montreal Can (0.04%). Company insiders that own Regeneron Pharmaceuticals stock include Arthur F Ryan, Charles A Baker, Douglas S Mccorkle, George Yancopoulos, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Peter Powchik, Plew Daniel P Van, Robert J Terifay and Sanofi. View Institutional Ownership Trends for Regeneron Pharmaceuticals.

Who sold Regeneron Pharmaceuticals stock? Who is selling Regeneron Pharmaceuticals stock?

Regeneron Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Advisors LLC, Rockefeller Financial Services Inc., APG Asset Management N.V., Russell Investments Group Ltd., Bank of Montreal Can, Oakbrook Investments LLC, Exxonmobil Investment Management Inc. TX and Cypress Asset Management Inc. TX. Company insiders that have sold Regeneron Pharmaceuticals stock in the last year include Arthur F Ryan, Charles A Baker, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos and Robert J Terifay. View Insider Buying and Selling for Regeneron Pharmaceuticals.

Who bought Regeneron Pharmaceuticals stock? Who is buying Regeneron Pharmaceuticals stock?

Regeneron Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Chevy Chase Trust Holdings Inc., Barometer Capital Management Inc., Mn Services Vermogensbeheer B.V., Aperio Group LLC, National Pension Service, Deane Retirement Strategies Inc., Sheets Smith Wealth Management and Acadian Asset Management LLC. View Insider Buying and Selling for Regeneron Pharmaceuticals.

How do I buy Regeneron Pharmaceuticals stock?

Shares of Regeneron Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Regeneron Pharmaceuticals' stock price today?

One share of Regeneron Pharmaceuticals stock can currently be purchased for approximately $513.45.


MarketBeat Community Rating for Regeneron Pharmaceuticals (NASDAQ REGN)
Community Ranking:  2.9 out of 5 ( )
Outperform Votes:  917 (Vote Outperform)
Underperform Votes:  687 (Vote Underperform)
Total Votes:  1,604
MarketBeat's community ratings are surveys of what our community members think about Regeneron Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 15 Hold Ratings, 11 Buy Ratings
Consensus Rating:Hold (Score: 2.42)
Consensus Price Target: $472.96 (7.89% downside)

Analysts' Ratings History for Regeneron Pharmaceuticals (NASDAQ:REGN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/22/2017Barclays PLCReiterated RatingEqual Weight$400.00 -> $450.00LowView Rating Details
7/21/2017BMO Capital MarketsReiterated RatingMarket Perform$421.00 -> $484.00LowView Rating Details
7/21/2017Bank of America CorporationReiterated RatingBuy$589.00 -> $593.00LowView Rating Details
7/14/2017Credit Suisse GroupDowngradeHold$485.00LowView Rating Details
7/10/2017Morgan StanleyReiterated RatingEqual Weight$405.00 -> $450.00MediumView Rating Details
6/30/2017BTIG ResearchReiterated RatingBuy -> Buy$480.00 -> $540.00HighView Rating Details
6/28/2017Leerink SwannReiterated RatingOutperform$493.00 -> $573.00LowView Rating Details
6/26/2017Sanford C. BernsteinDowngradeOutperform -> Market Perform$410.00 -> $480.00LowView Rating Details
6/22/2017Raymond James Financial, Inc.Reiterated RatingOutperform$475.00 -> $547.00MediumView Rating Details
6/20/2017Canaccord GenuitySet Price TargetBuy$484.00LowView Rating Details
6/20/2017Piper Jaffray CompaniesBoost Price TargetOverweight -> Overweight$446.00 -> $557.00LowView Rating Details
6/14/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldLowView Rating Details
5/15/2017Cowen and CompanyReiterated RatingHold$380.00LowView Rating Details
4/12/2017Jefferies Group LLCReiterated RatingHold$357.00LowView Rating Details
3/28/2017Robert W. BairdReiterated RatingNeutral$369.00LowView Rating Details
3/17/2017CIBCInitiated CoverageMarket Perform -> Market PerformLowView Rating Details
2/16/2017Goldman Sachs Group, Inc. (The)DowngradeBuy -> NeutralN/AView Rating Details
2/10/2017Citigroup Inc.Reiterated RatingBuy$420.00N/AView Rating Details
1/22/2017J P Morgan Chase & CoSet Price TargetHold$440.00N/AView Rating Details
1/10/2017Wells Fargo & CompanyReiterated RatingMarket PerformN/AView Rating Details
1/8/2017Evercore ISISet Price TargetHold$421.00N/AView Rating Details
1/6/2017Royal Bank Of CanadaReiterated RatingOutperform$626.00 -> $598.00N/AView Rating Details
1/6/2017Chardan CapitalLower Price TargetNeutral$350.00 -> $345.00N/AView Rating Details
12/28/2016ArgusReiterated RatingBuy$450.00N/AView Rating Details
10/28/2016Roth CapitalSet Price TargetBuy$520.00N/AView Rating Details
8/5/2016Brean CapitalReiterated RatingBuy$489.00N/AView Rating Details
3/17/2016SunTrust Banks, Inc.Lower Price TargetNeutral$450.00 -> $410.00N/AView Rating Details
3/15/2016GabelliInitiated CoverageBuy$574.00N/AView Rating Details
8/4/2015Deutsche Bank AGReiterated RatingBuy$650.00 -> $720.00N/AView Rating Details
(Data available from 7/26/2015 forward)

Earnings

Earnings History for Regeneron Pharmaceuticals (NASDAQ:REGN)
Earnings by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)
Earnings History by Quarter for Regeneron Pharmaceuticals (NASDAQ REGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2017        
5/4/2017Q1 2017$2.50$2.92$1.30 billion$1.32 billionViewListenView Earnings Details
2/9/2017Q4 2016$3.03$3.04$1.30 billion$1.23 billionViewListenView Earnings Details
11/4/2016Q316$2.73$3.13$1.29 billion$1.22 billionViewN/AView Earnings Details
8/4/2016Q216$2.65$2.82$1.24 billion$1.21 billionViewN/AView Earnings Details
5/5/2016Q116$2.58$2.57$1.18 billion$1.20 billionViewN/AView Earnings Details
2/9/2016Q415$3.40$2.83$1.17 billion$1.10 billionViewListenView Earnings Details
11/4/2015Q315$2.62$3.47$1.05 billion$1.14 billionViewListenView Earnings Details
8/4/2015Q215$2.77$2.89$887.03 million$999.00 millionViewListenView Earnings Details
5/7/2015Q115$2.50$2.88$820.30 million$870.00 millionViewN/AView Earnings Details
2/10/2015Q414$2.78$2.79$775.42 million$802.00 millionViewN/AView Earnings Details
11/4/2014Q314$2.57$2.52$733.04 million$726.00 millionViewN/AView Earnings Details
8/5/2014Q214$2.30$2.47$647.99 million$666.00 millionViewN/AView Earnings Details
5/8/2014Q114$0.94$0.58$609.04 million$626.00 millionViewN/AView Earnings Details
2/11/2014Q413$0.97$2.24$579.17 million$610.00 millionViewN/AView Earnings Details
11/5/2013Q313$0.92$2.40$501.93 million$597.00 millionViewN/AView Earnings Details
8/6/2013Q2 2013$0.92$1.73$470.63 million$458.00 millionViewN/AView Earnings Details
5/3/2013Q1 2013$1.46$1.78$424.26 million$440.00 millionViewN/AView Earnings Details
2/14/2013Q4 2012$1.11$1.47$392.64 million$415.00 millionViewN/AView Earnings Details
10/24/2012$1.14$1.89ViewN/AView Earnings Details
7/25/2012$0.45$0.90ViewN/AView Earnings Details
4/26/2012($0.33)$0.37ViewN/AView Earnings Details
2/13/2012($0.60)($0.37)ViewN/AView Earnings Details
7/28/2011($0.40)($0.69)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Regeneron Pharmaceuticals (NASDAQ:REGN)
Current Year EPS Consensus Estimate: $10.52 EPS
Next Year EPS Consensus Estimate: $12.1 EPS

Dividends

Dividend History for Regeneron Pharmaceuticals (NASDAQ:REGN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Regeneron Pharmaceuticals (NASDAQ:REGN)
Insider Ownership Percentage: 10.40%
Institutional Ownership Percentage: 66.89%
Insider Trades by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)
Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)
Insider Trades by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/22/2017Michael S AbermanSVPSell2,269$532.42$1,208,060.98View SEC Filing  
6/22/2017Neil StahlEVPSell8,306$532.55$4,423,360.30View SEC Filing  
6/20/2017Michael S BrownDirectorSell3,000$500.00$1,500,000.00View SEC Filing  
6/16/2017Robert J TerifayEVPSell21,147$468.19$9,900,813.93View SEC Filing  
6/15/2017Neil StahlEVPSell8,567$468.45$4,013,211.15View SEC Filing  
6/9/2017Joseph L GoldsteinDirectorSell1,000$482.55$482,550.00View SEC Filing  
6/2/2017Neil StahlEVPSell2,812$479.49$1,348,325.88View SEC Filing  
6/2/2017SanofiMajor ShareholderBuy136,050$478.17$65,055,028.50View SEC Filing  
5/25/2017P Roy VagelosChairmanSell9,295$458.14$4,258,411.30View SEC Filing  
5/12/2017Michael S BrownDirectorSell3,000$450.00$1,350,000.00View SEC Filing  
3/29/2017Michael S BrownDirectorSell1,000$400.00$400,000.00View SEC Filing  
1/11/2017SanofiMajor ShareholderBuy87,298$369.71$32,274,943.58View SEC Filing  
12/12/2016Charles A BakerDirectorSell3,000$392.02$1,176,060.00View SEC Filing  
11/15/2016Arthur F RyanDirectorSell2,000$429.34$858,680.00View SEC Filing  
11/14/2016Joseph L GoldsteinDirectorSell2,125$450.00$956,250.00View SEC Filing  
7/29/2016Joseph L GoldsteinDirectorSell2,125$425.00$903,125.00View SEC Filing  
6/14/2016SanofiMajor ShareholderBuy64,731$363.86$23,553,021.66View SEC Filing  
5/24/2016Arthur F RyanDirectorSell1,000$396.64$396,640.00View SEC Filing  
5/18/2016Plew Daniel P VanEVPSell4,413$385.77$1,702,403.01View SEC Filing  
4/6/2016Joseph L GoldsteinDirectorSell2,000$425.00$850,000.00View SEC Filing  
3/21/2016Joseph L GoldsteinDirectorSell2,000$375.00$750,000.00View SEC Filing  
2/17/2016SanofiMajor ShareholderBuy161,157$392.46$63,247,676.22View SEC Filing  
1/12/2016SanofiMajor ShareholderBuy83,938$465.04$39,034,527.52View SEC Filing  
12/29/2015Douglas S. MccorkleVPSell3,954$552.08$2,182,924.32View SEC Filing  
12/10/2015Michael S. BrownDirectorSell3,000$546.45$1,639,350.00View SEC Filing  
12/2/2015George YancopoulosinsiderSell43,348$549.03$23,799,352.44View SEC Filing  
11/18/2015P Roy VagelosChairmanSell17,240$587.90$10,135,396.00View SEC Filing  
11/10/2015Plew Daniel P. VanSVPSell5,123$554.85$2,842,496.55View SEC Filing  
11/9/2015Neil StahlEVPSell42,101$561.45$23,637,606.45View SEC Filing  
11/3/2015P Roy VagelosChairmanSell17,242$580.19$10,003,635.98View SEC Filing  
11/2/2015George YancopoulosinsiderSell43,348$571.61$24,778,150.28View SEC Filing  
10/6/2015SanofiMajor ShareholderBuy80,538$459.71$37,024,123.98View SEC Filing  
9/23/2015SanofiMajor ShareholderBuy147,209$534.67$78,708,236.03View SEC Filing  
9/21/2015Michael S. BrownDirectorSell3,000$551.55$1,654,650.00View SEC Filing  
9/17/2015Charles A. BakerDirectorSell5,000$550.00$2,750,000.00View SEC Filing  
8/14/2015Peter PowchikSVPSell23,485$573.38$13,465,829.30View SEC Filing  
7/15/2015Joseph L GoldsteinDirectorSell2,000$550.00$1,100,000.00View SEC Filing  
6/22/2015Joseph L GoldsteinDirectorSell2,000$526.85$1,053,700.00View SEC Filing  
5/27/2015Robert Alexander IngramDirectorSell1,379$513.39$707,964.81View SEC Filing  
5/26/2015Plew Daniel P VanSVPSell18,370$508.42$9,339,675.40View SEC Filing  
5/22/2015Douglas S MccorkleVPSell13,000$515.60$6,702,800.00View SEC Filing  
5/22/2015Joseph L GoldsteinDirectorSell4,000$514.28$2,057,120.00View SEC Filing  
5/15/2015Michael S BrownDirectorSell5,000$495.00$2,475,000.00View SEC Filing  
3/25/2015Charles A BakerDirectorSell5,000$454.96$2,274,800.00View SEC Filing  
3/24/2015Michael S AbermanSVPSell4,843$478.99$2,319,748.57View SEC Filing  
3/18/2015Michael S AbermanSVPSell3,442$465.00$1,600,530.00View SEC Filing  
3/17/2015Robert J TerifaySVPSell10,993$451.01$4,957,952.93View SEC Filing  
3/16/2015Joseph J LarosaSVPSell18,311$450.00$8,239,950.00View SEC Filing  
2/27/2015Douglas S MccorkleVPSell3,000$416.24$1,248,720.00View SEC Filing  
2/26/2015Marc Tessier-LavigneDirectorSell3,000$421.95$1,265,850.00View SEC Filing  
2/24/2015Robert J TerifaySVPSell11,173$423.67$4,733,664.91View SEC Filing  
2/23/2015Plew Daniel P VanSVPSell9,431$427.82$4,034,770.42View SEC Filing  
2/20/2015Joseph L GoldsteinDirectorSell5,000$423.65$2,118,250.00View SEC Filing  
2/17/2015Michael S AbermanSVPSell3,692$404.46$1,493,266.32View SEC Filing  
1/2/2015Leonard S SchleiferCEOSell1,500$410.58$615,870.00View SEC Filing  
1/2/2015Peter PowchikSVPSell10,822$414.08$4,481,173.76View SEC Filing  
12/24/2014SanofiMajor ShareholderBuy201,459$393.21$79,215,693.39View SEC Filing  
12/16/2014Douglas S MccorkleVPSell8,486$410.15$3,480,532.90View SEC Filing  
11/24/2014Alfred G GilmanDirectorSell40,000$408.44$16,337,600.00View SEC Filing  
11/24/2014Neil StahlSVPSell5,307$412.93$2,191,419.51View SEC Filing  
11/18/2014Robert J TerifaySVPSell22,362$405.79$9,074,275.98View SEC Filing  
11/13/2014Plew Daniel P VanSVPSell8,575$399.34$3,424,340.50View SEC Filing  
11/12/2014Joseph L GoldsteinDirectorSell5,000$398.31$1,991,550.00View SEC Filing  
11/12/2014Leonard S SchleiferCEOSell45,817$400.30$18,340,545.10View SEC Filing  
10/28/2014Leonard S SchleiferCEOSell69,112$404.01$27,921,939.12View SEC Filing  
10/24/2014Michael S BrownDirectorSell5,000$399.00$1,995,000.00View SEC Filing  
10/24/2014Murray A GoldbergSVPSell26,788$400.70$10,733,951.60View SEC Filing  
9/16/2014SanofiMajor ShareholderBuy31,717$349.26$11,077,479.42View SEC Filing  
9/15/2014SanofiMajor ShareholderBuy140,632$345.15$48,539,134.80View SEC Filing  
9/10/2014P Roy VagelosChairmanSell10,328$350.07$3,615,522.96View SEC Filing  
8/27/2014Joseph L GoldsteinDirectorSell2,000$350.31$700,620.00View SEC Filing  
8/19/2014Michael S AbermanVPSell3,611$350.00$1,263,850.00View SEC Filing  
8/18/2014Douglas S MccorkleVPSell5,875$353.00$2,073,875.00View SEC Filing  
8/15/2014Michael S BrownDirectorSell3,000$349.20$1,047,600.00View SEC Filing  
8/14/2014Joseph L GoldsteinDirectorSell2,000$347.65$695,300.00View SEC Filing  
8/13/2014P Roy VagelosChairmanSell8,028$340.01$2,729,600.28View SEC Filing  
8/11/2014Neil StahlSVPSell11,646$339.96$3,959,174.16View SEC Filing  
8/11/2014P Roy VagelosChairmanSell11,972$340.11$4,071,796.92View SEC Filing  
8/8/2014Neil StahlSVPSell2,841$340.60$967,644.60View SEC Filing  
8/7/2014Plew Daniel P VanSVPSell6,806$338.37$2,302,946.22View SEC Filing  
8/6/2014Joseph L GoldsteinDirectorSell2,000$331.20$662,400.00View SEC Filing  
7/15/2014SanofiMajor ShareholderBuy129,100$314.92$40,656,172.00View SEC Filing  
7/14/2014SanofiMajor ShareholderBuy300,000$316.80$95,040,000.00View SEC Filing  
7/10/2014SanofiMajor ShareholderBuy175,000$311.08$54,439,000.00View SEC Filing  
7/9/2014SanofiMajor ShareholderBuy348,000$309.76$107,796,480.00View SEC Filing  
7/7/2014SanofiMajor ShareholderBuy356,700$312.37$111,422,379.00View SEC Filing  
7/2/2014SanofiMajor ShareholderBuy212,400$307.25$65,259,900.00View SEC Filing  
7/1/2014SanofiMajor ShareholderBuy212,400$300.20$63,762,480.00View SEC Filing  
6/30/2014SanofiMajor ShareholderBuy262,400$281.17$73,779,008.00View SEC Filing  
5/23/2014Plew Daniel VanSVPSell5,369$295.93$1,588,848.17View SEC Filing  
5/19/2014Sanofimajor shareholderBuy190,751$300.04$57,232,930.04View SEC Filing  
3/28/2014Sanofimajor shareholderBuy306,945$306.73$94,149,239.85View SEC Filing  
3/27/2014Sanofimajor shareholderBuy306,945$311.01$95,462,964.45View SEC Filing  
3/24/2014Charles BakerDirectorSell15,000$302.67$4,540,050.00View SEC Filing  
3/24/2014Sanofimajor shareholderBuy306,945$307.91$94,511,434.95View SEC Filing  
3/21/2014Sanofimajor shareholderBuy305,115$321.22$98,009,040.30View SEC Filing  
3/20/2014Sanofimajor shareholderBuy67,703$328.33$22,228,925.99View SEC Filing  
3/17/2014Michael BrownDirectorSell2,000$334.29$668,580.00View SEC Filing  
3/17/2014Sanofimajor shareholderBuy115,711$328.46$38,006,435.06View SEC Filing  
3/12/2014Sanofimajor shareholderBuy220,995$334.69$73,964,816.55View SEC Filing  
3/11/2014Sanofimajor shareholderBuy380,532$330.41$125,731,578.12View SEC Filing  
3/7/2014Sanofimajor shareholderBuy150,277$328.72$49,399,055.44View SEC Filing  
3/3/2014Sanofimajor shareholderBuy251,594$338.12$85,068,963.28View SEC Filing  
2/27/2014Michael BrownDirectorSell1,000$335.00$335,000.00View SEC Filing  
2/25/2014Joseph GoldsteinDirectorSell1,000$338.86$338,860.00View SEC Filing  
2/25/2014Murray GoldbergSVPSell11,871$339.55$4,030,798.05View SEC Filing  
2/21/2014Alfred GilmanDirectorSell5,000$340.00$1,700,000.00View SEC Filing  
2/21/2014Murray GoldbergSVPSell21,258$336.51$7,153,529.58View SEC Filing  
2/20/2014Joseph GoldsteinDirectorSell1,000$326.99$326,990.00View SEC Filing  
2/18/2014Michael AbermanVPSell3,648$331.42$1,209,020.16View SEC Filing  
2/18/2014Robert TerifaySVPSell12,865$332.68$4,279,928.20View SEC Filing  
2/13/2014Neil StahlSVPSell22,612$318.82$7,209,157.84View SEC Filing  
2/12/2014George YancopoulosInsiderSell88,987$320.33$28,505,205.71View SEC Filing  
2/12/2014Joseph GoldsteinDirectorSell1,000$320.62$320,620.00View SEC Filing  
2/11/2014Alfred GilmanDirectorSell5,000$320.00$1,600,000.00View SEC Filing  
2/11/2014Douglas MccorkleVPSell5,819$325.00$1,891,175.00View SEC Filing  
2/11/2014P Roy VagelosChairmanSell11,475$325.10$3,730,522.50View SEC Filing  
2/7/2014Sanofimajor shareholderBuy168,511$286.78$48,325,584.58View SEC Filing  
2/5/2014Sanofimajor shareholderBuy397,264$284.12$112,870,647.68View SEC Filing  
2/3/2014Sanofimajor shareholderBuy208,972$283.78$59,302,074.16View SEC Filing  
1/28/2014Sanofimajor shareholderBuy157,920$275.90$43,570,128.00View SEC Filing  
1/14/2014Alfred GilmanDirectorSell5,000$300.00$1,500,000.00View SEC Filing  
1/14/2014Douglas MccorkleVPSell4,000$290.00$1,160,000.00View SEC Filing  
1/2/2014Peter PowchikSVPSell20,668$274.77$5,678,946.36View SEC Filing  
12/20/2013Peter PowchikSVPSell9,133$270.21$2,467,827.93View SEC Filing  
11/26/2013George SingDirectorSell10,000$295.00$2,950,000.00View SEC Filing  
11/6/2013Joseph GoldsteinDirectorSell1,000$300.74$300,740.00View SEC Filing  
9/19/2013Leonard SchleiferCEOSell102,949$302.67$31,159,573.83View SEC Filing  
9/19/2013P Roy VagelosChairmanSell145,356$302.86$44,022,518.16View SEC Filing  
9/18/2013Plew Daniel VanSVPSell23,977$303.17$7,269,107.09View SEC Filing  
9/18/2013William RobertsVPSell15,000$304.00$4,560,000.00View SEC Filing  
9/9/2013Leonard S SchleiferCEOSell5,000$275.47$1,377,350.00View SEC Filing  
8/23/2013Joseph GoldsteinDirectorSell1,000$238.29$238,290.00View SEC Filing  
6/10/2013Charles A BakerDirectorSell15,000$251.84$3,777,600.00View SEC Filing  
5/31/2013Arthur F RyanDirectorSell2,500$249.55$623,875.00View SEC Filing  
5/28/2013Joseph L GoldsteinDirectorSell4,000$252.20$1,008,800.00View SEC Filing  
5/21/2013Murray A GoldbergCFOSell66,835$259.74$17,359,722.90View SEC Filing  
5/17/2013Michael S BrownDirectorSell15,000$275.19$4,127,850.00View SEC Filing  
5/14/2013Michael S AbermanVPSell5,529$279.61$1,545,963.69View SEC Filing  
5/13/2013Neil StahlSVPSell23,038$276.88$6,378,761.44View SEC Filing  
5/10/2013George L SingDirectorSell5,000$270.00$1,350,000.00View SEC Filing  
5/8/2013Robert J TerifaySVPSell8,231$261.23$2,150,184.13View SEC Filing  
5/6/2013P Roy VagelosChairmanSell12,018$263.15$3,162,536.70View SEC Filing  
11/27/2012P Roy VagelosChairmanSell64,753$175.22$11,346,020.66View SEC Filing  
11/26/2012Charles A BakerDirectorSell15,000$173.87$2,608,050.00View SEC Filing  
11/14/2012Michael S BrownDirectorSell7,000$147.03$1,029,210.00View SEC Filing  
11/1/2012Arthur F RyanDirectorSell10,000$145.57$1,455,700.00View SEC Filing  
9/6/2012Charles A BakerDirectorSell15,000$150.00$2,250,000.00View SEC Filing  
8/23/2012George L SingDirectorSell10,000$140.50$1,405,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Regeneron Pharmaceuticals (NASDAQ:REGN)
Latest Headlines for Regeneron Pharmaceuticals (NASDAQ:REGN)
Source:
DateHeadline
marketwatch.com logoHealth-care fund managers say a spike in drugs and devices will produce big returns - MarketWatch
www.marketwatch.com - July 26 at 6:45 AM
finanznachrichten.de logoPro-Trader Daily: Featured Company News - Regeneron and Sanofi Receive Positive CHMP's Opinion for Dupixent(R)
www.finanznachrichten.de - July 24 at 5:55 PM
finance.yahoo.com logoFeatured Company News - Regeneron and Sanofi Receive Positive CHMP's Opinion for Dupixent(R)
finance.yahoo.com - July 24 at 5:55 PM
americanbankingnews.com logoRegeneron Pharmaceuticals, Inc. (REGN) Given "Equal Weight" Rating at Barclays PLC
www.americanbankingnews.com - July 22 at 6:28 PM
nasdaq.com logoTesla Moves Up In Market Cap Rank, Passing Regeneron Pharmaceuticals - Nasdaq
www.nasdaq.com - July 22 at 8:09 AM
finance.yahoo.com logoSanofi and Regeneron Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis
finance.yahoo.com - July 22 at 8:09 AM
americanbankingnews.com logoRegeneron Pharmaceuticals' (NASDAQ:REGN) "Market Perform" Rating Reaffirmed at BMO Capital Markets
www.americanbankingnews.com - July 21 at 1:44 PM
americanbankingnews.com logoRegeneron Pharmaceuticals, Inc. (REGN) Given Buy Rating at Bank of America Corporation
www.americanbankingnews.com - July 21 at 12:30 PM
investorplace.com logo3 Big Stock Charts for Thursday: Tripadvisor Inc (TRIP), Regeneron Pharmaceuticals Inc (REGN) and Lam Research ... - Investorplace.com
investorplace.com - July 21 at 6:37 AM
finance.yahoo.com logoStocks End Tightly Mixed; These 4 Drugmakers Prop Nasdaq, S&P 500
finance.yahoo.com - July 21 at 6:37 AM
investorplace.com logo3 Big Stock Charts for Thursday: Tripadvisor Inc (TRIP), Regeneron Pharmaceuticals Inc (REGN) and Lam Research Corporation (LRCX)
investorplace.com - July 20 at 12:30 PM
americanbankingnews.com logoCredit Suisse Group Lowers Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to Hold
www.americanbankingnews.com - July 15 at 1:40 PM
finance.yahoo.com logoRegeneron to Report Second Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2017
finance.yahoo.com - July 14 at 7:50 AM
finance.yahoo.com logoRegeneron Announces the 2017 Winners of the Regeneron Prize for Creative Innovation
finance.yahoo.com - July 13 at 8:39 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Regeneron Pharmaceuticals, Inc. (REGN) Will Post Quarterly Sales of $1.36 Billion
www.americanbankingnews.com - July 12 at 9:52 AM
americanbankingnews.com logoRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Rating Reiterated by Morgan Stanley
www.americanbankingnews.com - July 10 at 10:20 PM
americanbankingnews.com logo$2.67 Earnings Per Share Expected for Regeneron Pharmaceuticals, Inc. (REGN) This Quarter
www.americanbankingnews.com - July 10 at 6:22 PM
americanbankingnews.com logoRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Downgraded by BidaskClub to Buy
www.americanbankingnews.com - July 6 at 8:29 PM
americanbankingnews.com logoZacks Investment Research Lowers Regeneron Pharmaceuticals, Inc. (REGN) to Hold
www.americanbankingnews.com - July 4 at 1:06 PM
americanbankingnews.com logoRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - July 3 at 8:44 PM
americanbankingnews.com logoLeerink Swann Reaffirms "Outperform" Rating for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
www.americanbankingnews.com - July 2 at 1:20 PM
seekingalpha.com logoRegeneron price target boosted at BTIG - Seeking Alpha
seekingalpha.com - July 2 at 6:47 AM
finance.yahoo.com logoCorporate News Blog - Regeneron and Sanofi Announced Kevzara Approval by the European Commission
finance.yahoo.com - July 1 at 6:57 AM
finance.yahoo.com logoNike, Micron, Regeneron Get Price Target Hikes; Walgreens Is A Buy
finance.yahoo.com - July 1 at 6:57 AM
americanbankingnews.com logoRegeneron Pharmaceuticals, Inc. (REGN) PT Raised to $540.00
www.americanbankingnews.com - June 30 at 7:54 AM
nasdaq.com logoNoteworthy Thursday Option Activity: SIG, MET, REGN - Nasdaq
www.nasdaq.com - June 30 at 6:05 AM
finance.yahoo.com logoStrongbridge (SBBP) Shows Strength: Stock Moves Up 10.1%
finance.yahoo.com - June 29 at 6:28 AM
finance.yahoo.com logoAmgen Gets Positive CHMP Opinion for Mimpara Label Expansion
finance.yahoo.com - June 27 at 7:35 PM
finance.yahoo.com logoSanofi/Regeneron's Kevzara Gets Marketing Approval in EU
finance.yahoo.com - June 27 at 7:35 PM
finance.yahoo.com logoRegeneron: The More the Merrier?
finance.yahoo.com - June 27 at 7:35 PM
finance.yahoo.com logoRegeneron Pharmaceuticals Has a Powerful Base Pattern But Looks Extended
finance.yahoo.com - June 27 at 7:35 PM
finance.yahoo.com logoDow Component Merck Fails To Impress With Cholesterol-Busting Drug
finance.yahoo.com - June 27 at 7:35 PM
nasdaq.com logoRegeneron: EC Okays Kevzara To Treat Moderately To Severely Active RA
www.nasdaq.com - June 27 at 7:47 AM
prnewswire.com logoRegeneron and Sanofi Announce Approval of Kevzara® (sarilumab) to Treat Adult ...
www.prnewswire.com - June 27 at 7:47 AM
finance.yahoo.com logoIs It Time To Step To The Sidelines On Regeneron?
finance.yahoo.com - June 27 at 7:47 AM
finance.yahoo.com logoRegeneron and Sanofi Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union
finance.yahoo.com - June 27 at 7:47 AM
finance.yahoo.com logoSanofi and Regeneron Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union
finance.yahoo.com - June 27 at 7:47 AM
americanbankingnews.com logoRegeneron Pharmaceuticals, Inc. (REGN) Downgraded by Sanford C. Bernstein
www.americanbankingnews.com - June 26 at 12:16 PM
americanbankingnews.com logoRegeneron Pharmaceuticals, Inc. (REGN) Rating Increased to Strong-Buy at BidaskClub
www.americanbankingnews.com - June 24 at 4:26 PM
streetinsider.com logoRegeneron (REGN) Details Royalty Agreement with Novartis for ACZ885 - StreetInsider.com
www.streetinsider.com - June 24 at 1:22 AM
zacks.com logoRegeneron (REGN) Stock on Fire: What's Behind the Surge?
www.zacks.com - June 23 at 8:22 PM
finance.yahoo.com logoRegeneron (REGN) Stock on Fire: What's Behind the Surge?
finance.yahoo.com - June 23 at 8:22 PM
finance.yahoo.com logoBiotech Movers: Regeneron Slides Back After Big Gains
finance.yahoo.com - June 23 at 8:22 PM
finance.yahoo.com logoSonic, Forestar post gains; BlackBerry, Regeneron fall
finance.yahoo.com - June 23 at 8:22 PM
americanbankingnews.com logoMichael S. Aberman Sells 2,269 Shares of Regeneron Pharmaceuticals, Inc. (REGN) Stock
www.americanbankingnews.com - June 23 at 7:15 PM
americanbankingnews.com logoInsider Selling: Regeneron Pharmaceuticals, Inc. (REGN) EVP Sells 8,306 Shares of Stock
www.americanbankingnews.com - June 23 at 7:14 PM
americanbankingnews.com logoStock Traders Purchase Large Volume of Put Options on Regeneron Pharmaceuticals (REGN)
www.americanbankingnews.com - June 23 at 12:37 PM
latimes.com logoU.S. stocks slip in early trading
www.latimes.com - June 23 at 10:59 AM
streetinsider.com logoRegeneron (REGN) Details Royalty Agreement with Novartis for ACZ885
www.streetinsider.com - June 23 at 9:33 AM
reuters.com logoBRIEF-Regeneron details royalty agreement with Novartis for canakinumab
www.reuters.com - June 23 at 9:33 AM

Social

Chart

Regeneron Pharmaceuticals (REGN) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by MarketBeat.com Staff